C
프레스티지바이오로직스
334970KOSDAQ46.0 / 100
Reference Date: 2026-10-23
Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 9.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Prestige BioLogics specializes in contract manufacturing of advanced biopharmaceuticals for domestic and international pharmaceutical companies, offering customized services throughout the development process via its CDEMO business model. In the first half of 2024, antibody drug sales accounted for 68% of total revenue.
Number of Employees
279people
Average Salary
42.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.71Industry Average 1.205.5Point
Lower than industry avg (good)
ROE
-26.56Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
24.16Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲251.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼26.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -30.4% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 1,235Won52-week high 3,77052-week low 1,235
1-month return1.0Point
1m -9.59% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral기타주요경영사항 (주식병합결정 철회)2026-09-30
- Neutral[기재정정]주식병합결정 (철회)2026-09-30
- Neutral정기주주총회결과2026-09-30
- Neutral[기재정정]사업보고서 (2026.06)2026-09-28